Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2017 | New IDEAS: biomarkers in AD patient outcomes

Liana Apostolova • 17 Aug 2017
AAIC 2017
Alzheimer’s Disease

The identification of biomarkers relating to Alzheimer’s disease (AD) has led to significant advances in our understanding of the disorder. Liana Apostolova, MD, MS from Indiana University School of Medicine, Indianapolis, IN speaks with us about how biomarkers have improved the field, and describes the IDEAS project (NCT02420756), a longitudinal cohort study examining the impact of amyloid PET scans on AD patient outcomes. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) in London, UK.

More from Liana Apostolova

Characterizing co-pathologies: a hot topic in the field of Alzheimer's disease
2:18
Characterizing co-pathologies: a hot topic in the field of Alzheimer's disease
Liana Apostolova • 17 Aug 2017
The challenges of diagnosing Alzheimer’s disease
1:50
The challenges of diagnosing Alzheimer’s disease
Liana Apostolova • 17 Aug 2017
What do biomarkers mean for the treatment of Alzheimer’s disease?
0:51
What do biomarkers mean for the treatment of Alzheimer’s disease?
Liana Apostolova • 17 Aug 2017
Late and early-onset AD: understanding the differences
2:29
Late and early-onset AD: understanding the differences
Liana Apostolova • 17 Aug 2017

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals